Wisteria floribunda agglutinin-positive human Mac-2-binding protein as a predictive marker of liver fibrosis in HIV/HCV co-infected patients.
In human immunodeficiency virus (HIV) and hepatitis C virus (HCV) co-infected patients, the progression of liver failure is reported to be more aggressive than that in HCV mono-infected patients. Wisteria floribunda agglutinin-positive human Mac-2-binding protein (WFA+ -M2BP) is well recognized as a liver fibrosis glycobiomarker with a unique fibrosis-related glycoalteration. We analyzed HIV/HCV co-infected patients' M2BP levels as a possible marker for predicting liver fibrosis. M2BP was measured in 31 HIV/HCV co-infected patients, and we analyzed the correlation between WFA+ -M2BP and several markers of fibrosis, liver function, and tumor markers. We compared the WFA+ -M2BP levels in HIV/HCV co-infected patients with those of HCV mono-infected patients by performing a propensity score matching analysis. In the HIV/HCV co-infected patients, the serum level of WFA+ -M2BP was well correlated with the markers type IV collagen, hyaluronic acid, and alfa-fetoprotein but not PIVKA-II. In the propensity score matching with HCV mono-infected patients, the WFA+ -M2BP levels were significantly higher in the HIV/HCV co-infected patients compared to the levels in the HCV mono-infected patients. In conclusion, WFA+ -M2BP might be feasible a predictive marker of fibrosis in HIV/HCV co-infected patients.